Introduction
In 1969 AMD Research Project 149 was initiated to study the incidence of chloroquine-resistant falciparum malaria in Commonwealth troops operating in the Far East. The findings were reported by McKelvey et all in 1971. In association with this work an investigation into the levels of Paludrine (proguanil hydrochloride lel) in the plasma of troops on various dose regimes was undertaken. The results of this study have never been published and this belated report has been stimulated by two facts: a. the' Army continues to use Paludrine as its standard chemoprophylactic, and b. there has been a resurgence of interest in this drui, 3, 4 The Army adopted Paludrine, first synthesised in November 1944, as a prophylactic, and, alone or in combination, therapeutic drug in 194617 following the studies of Maegraith 5 and Fairley6. It replaced Mepacrine in these roles. It was more effective, safer, being almost free from side-effects, and was potentially cheaper.
Within four years there were reports in this Journaf and elsewhere of failures in prophylaxis. By 1956 the Army standard dose of lOOmglday had been doubled for personnel serving in West Africa in view of the apparent ineffectiveness of the lower dose in this area. Paludrine became increasingly unpopular in the world at large due to the reported incidence of drug-resistance and drugs such as chloroquine, with its alleged advantages of weekly dosage, were adopted by many. The Army continued to employ Paludrine as a prophylactic wishing to use different drugs for prophylaxis and therapy and in view of the importance of using a safe drug in massmedication. Regular reviews of the situation were instituted.
The history of chloroquine is well-known and it was to characterise chloroquine resistance in falciparum malaria according to the WHO protocol 8 that AMD Research Project 149 was undertaken. In addition as all personnel were under orders to take 100mg of Paludrine a day it was a logical step to study the levels of this drug actually present in the plasma under a variety of conditions, to some extent repeating the work of Maegraith et al 9 
Aims
The study set out to measure the plasma Paludrine levels in two groups of Servicemen: a. a group taking various dose regimes under strict supervision, (Phase 1) b. a sample of the troops participating in a large field exercise (Bersatu Padu) who were instructed to take 200mglday under unit arrangements (Phase 11) This exercise was held on the east coast of West Malaysia.
In this way the levels would be characterised under optimum and realistic field conditions.
It was also anticipated that some of the Phase 11 subjects might subsequently develop malaria at a time which would permit some estimate of the minimum plasma levels providing protection against the Plasmodium species to which they were exposed.
Methods
Assay was performed by the Central Pathology Laboratory Far East Land Forces (F ARELF) Singapore, using the method of Spinks and TotteylO, for which lOml of plasma are required, and was supported by a grant from ICI. The technique is considered accurate to ±5JLgll at plasma levels in excess of lOJLgll. To obtain repeated blood samples in excess of 20ml called for a degree of dedication on the part of the subjects, but with one small exception, entire subunits, as desired to minimise selection bias, volunteered to a man. In the Phase I study blood was taken at standard intervals, often every 24hr immediately before the next dose of Paludrine .. was due. The Phase 11 exercise activities made access to the volunteers difficult, but samples were obtained within an acceptable time frame. The blood was centrifuged as soon as possible and plasma samples stored in a freezer if necessary before assay. During Phase 11 a hand centrifuge was used and DEWorsley plasma stored in the ice-box of a domestic refrigerator until it could be flown to Singapore. There were other demands on the refrigerator.
Basic data on each subject, age weight, medical history and length of time in the theatre was recorded before sampling commenced. At the time of bleeding the subject was interrogated regarding his activity levels, any gastro-intestinal disturbance, fluid and alcohol intake and any other noteworthy event during the previous 24hr. Phase 11 subjects were asked when they had last taken Paludrine.
Results
253 volunteers participated in Phase I, including Australian, British, Gurkha, Malay, New Zealand and Singaporean troops. Phase 11 involved approx 100 I British Army and Royal Marine personnel.
Phase I A number of dose regimes were studied in Phase 1 but only the most relevant and interesting are considered here: a. Individual day-to-day variation. 22 men taking l00mg under supervision at the same time each day were bled on four successive days immediately before the next dose was due, at the time of the lowest plasma level within the 24hr period. This may be considered the plateau level 9 • Fig 1 demonstrates the wide individual variation which could not be correlated with activity, medical history or fluid intake, and the relation to body weight is barely detectable. b. Regular l00mg/day build-up and decay. A total of 47 men, none of whom had taken any chemoprophylaxis for at least a fortnight, commenced a supervised dose of 100mg at the same time each morning, continued for a minimum of seven days and then ceased. Blood was taken before each daily dose and on four days after administration stopped. group the plateau at 134JLg/l (sd 14) was at a lower level than in the former, Australian group.
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Phase 11
Conditions were less than ideal but the results from 352 blood samples drawn from almost 100 men who were under orders to take 100mg twice a day are summarised in Fig 5, which relates the levels measured to the stated number of hours since the previous tablet was taken. An attempt was made to divide the population into high and low activity groups. It is immediately apparent that throughout the plasma levels are lower than those which could be anticipated from the Phase I results. This is discussed below.
None of the troops studied in Phase 11 developed malaria, although an adjacent unit, which had been excluded from the study partly because of its reputation for excellent anti-malaria discipline, suffered a very high incidence.
Discussion
The salient facts which emerge from Phase I are reasonably self-evident. In the dose-regimes studied it is unlikely that men commencing administration will achieve peak plasma levels until the third day although the plateau as defined will be reached on the second day. It seems pharmacological sense to start Paludrine dosage three days before exposure, although on the grounds of establishing a regular habit there is much to be said for an earlier start, say one week.
A regime of two 100mg tablets once a day provides an increase in the plateau level from the 80JLg/l achieved with a single tablet daily to some 130JLg/l, while on 100mg twice a day a higher plateau of almost 160JLg/l is reached. Peak plasma levels were not investigated in this study but are thought likely to follow a similar pattern. These findings provide support for employing a 200mg/ day regime in divided doses, certainly if it is the plateau level which is more significant than the peak. However if one is so close to limit of effectiveness that the difference between 130 and 160JLg/l is critical, with a drug as safe as Paludrine there is a case for increasing the total daily dosage to 300mg.
The decay rates on the regimes studied are included for interest in the absence of any data on the minimum effective level in the strains to which the troops were exposed. The half-life appears to be about 48hr.
The levels found in Phase 11 are lower than anticipated. That this was due to the rigours of heavy physical work and associated sweating is not supported when the two activity groups are compared, nor is it believed that existing on field rations has some peculiar effect on pharmacology. That the conditions of storage and transport of the specimens was less than ideal cannot be denied and this may account for the differences. However the more experienced and cynical observer will find favour with the suggestion that there was a degree of poor Paludrine discipline in at least some of the troops on Bersatu Padu. The dramatic and totally unphysiological increase in plasma Paludrine levels found in the low activity group at 14 and 15hrs since stated last dose (Fig 5) may perhaps be explained by the guilty swallowing the odd tablet when the investigators transport hove in sight. These results based on the subjects recollection of when he last took a tablet, and the apparent anomalies revealed may well highlight the difficulties which arise on active service or on exercises when routine is disrupted, meals irregular and ideas of the day of the week blurred. The only fixed points, and even these may be missed, are dawn and dusk. This provides good justification for a daily or twice-daily prophylactic.
D EWorsley
No reference has been made to other anti-malaria precautions available to troops in the field as the aims of the study were .limited by the resources which could be deployed.
: It has alreadybeen recorded that the British Army has continued to use Paludrine since its adoption in 194617, and that as a result of experience the daily dose for West Africa was dou~led to 200mglday in 1956. This increase in dosage was made world-wide in 1982. During almost 40 years the ~rug has served well, and has never produced side~bffects of more than a trivial nature. Cases of malaria have occurred but it is fair to state that in many these were due to a failure to observe other antimalaria precautions associated with poor compliance with the chethoprophylatic regime, perhaps most typically during the post-exposure period which is often spent on leave."
There has been much pressure to change to alternative drugs such as chloroquine, Maloprim or Fansidar, and the situation has been kept under constant review, leading to the adoption of the standard 200mg/ day dose mentioned above. While the Army has far fewer permanent bases in malarious areas than in the past, (Belize and the New Territories of Hong Kong are the only two remaining), our troops do exercise in many parts of the world. Kenya is one of these and during the last four years some thousands of men have spent 4-6 weeks at a time training in different parts of that country from the highlands to the coastal strip. Their malaria experience initially on lOOmglday Paludrine and more recently 200mglday has been monitored, including assays of plasma and urine.
Between Jan 1983 and Nov 1984 of some 2500 troops exercising four developed malaria, (3 proven fa\Ciparum and 1 clinical fa\Ciparum). In two of these there was convincing evidence of failure of compliance with chemoprophylactic discipline. In Jan 1985 a unit of about 600 men suffered 18 cases (lO fa\Ciparum, 3 vivax, 1 mixed and 4 clinical) to be followed in May by a unit of 700 who produced 23 cases (20 fa\Ciparum, 1 mixed and 2 c1inical)lI. The reasons for this untoward incidence remain to be established and forthcoming exercises will be even more closely monitored.
It is recognised that it may be necessary for us to modify our chemoprophylactic regime by adding a drug of a different type to our standard Paludrine for certain parts of the world; Kenya may be one of these.
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Whichever drug or drugs are selected it is to be hoped that they at least approach Paludrine in their margin of safety, and that the hazards of chemoprophylaxis are infinitely less than the potential hazards of the disease.
